UroGen Pharma Announces Pricing of Initial Public Offering

May 3, 2017

RA'ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Market on May 4, 2017 under the ticker symbol "URGN." In addition, UroGen Pharma granted the underwriters a 30-day option to purchase up to an additional 671,005 ordinary shares. The offering is expected to close on or about May 9, 2017, subject to customary closing conditions.

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 3, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. Moreover, UroGen Pharma has recently completed a worldwide licensing agreement with Allergan Pharmaceuticals International Limited, a wholly owned subsidiary of Allergan plc, for the use of RTGel with neurotoxins for the treatment of overactive bladder and related conditions. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.

Forward Looking Statements
This press release contains forward-looking statements, including with respect to the expected closing of the initial public offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including that the conditions to the closing of the initial public offering are not satisfied. UroGen Pharma undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations.

CONTACT:
Gary Titus, UroGen Pharma Ltd.
689 Fifth Avenue, 14th Floor
New York, NY 10022
garyt@urogen.com
646-768-9531

Stephanie Carrington, ICR, Inc.
685 Third Avenue 2nd Floor
New York, NY 10017
stephanie.carrington@icrinc.com
646-277-1282